Advertisement
Editorial Commentary|Articles in Press

Unraveling the influence of genomic context on pleiotropy in SCN5A-mediated cardiac channelopathies: Insights from the Worm Study

  • John R. Giudicessi
    Correspondence
    Address reprint requests and correspondence: Dr John R. Giudicessi, Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
    Affiliations
    Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota
    Search for articles by this author
Published:February 27, 2023DOI:https://doi.org/10.1016/j.hrthm.2023.02.022
      Disease-causative variants in the SCN5A-encoded pore-forming α subunit of the Nav1.5 cardiac sodium channel cause a spectrum of electrical and structural genetic heart disorders including type 1 Brugada syndrome (BrS1; Nav1.5 loss-of-function), type 3 long QT syndrome (LQT3; Nav1.5 gain-of-function), multifocal ectopic Purkinje-related premature contractions (Nav1.5 gain-of-function), progressive cardiac conduction disease (PCCD; Nav1.5 loss-of-function), and dilated cardiomyopathy (Nav1.5 loss-of-function, gain-of-function, and overlapping functional effects).
      • Giudicessi J.R.
      • Ackerman M.J.
      Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes.
      ,
      • Wilde A.A.M.
      • Amin A.S.
      Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy.
      In addition, so-called SCN5A overlap syndromes, whereby the clinical and electrocardiographic features of more than one of the above disorders (eg, BrS1 plus LQT3 or LQT3 plus multifocal ectopic Purkinje-related premature contractions), are not infrequently observed in a single SCN5A variant–positive individual or across family members with the same disease-causative SCN5A variant.
      • Makita N.
      • Behr E.
      • Shimizu W.
      • et al.
      The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.
      ,
      • Barake W.
      • Giudicessi J.R.
      • Asirvatham S.J.
      • Ackerman M.J.
      Purkinje system hyperexcitability and ventricular arrhythmia risk in type 3 long QT syndrome.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Giudicessi J.R.
        • Ackerman M.J.
        Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes.
        Transl Res. 2013; 161: 1-14
        • Wilde A.A.M.
        • Amin A.S.
        Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy.
        JACC Clin Electrophysiol. 2018; 4: 569-579
        • Makita N.
        • Behr E.
        • Shimizu W.
        • et al.
        The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.
        J Clin Invest. 2008; 118: 2219-2229
        • Barake W.
        • Giudicessi J.R.
        • Asirvatham S.J.
        • Ackerman M.J.
        Purkinje system hyperexcitability and ventricular arrhythmia risk in type 3 long QT syndrome.
        Heart Rhythm. 2020; 17: 1768-1776
        • Veltmann C.
        • Barajas-Martinez H.
        • Wolpert C.
        • et al.
        Further insights in the most common SCN5A mutation causing overlapping phenotype of long QT syndrome, Brugada syndrome, and conduction defect.
        J Am Heart Assoc. 2016; 5e003379
        • Hohmann S.
        • Rudic B.
        • Konrad T.
        • et al.
        Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.
        Europace. 2017; 19: 1723-1729
        • Kapplinger J.D.
        • Tester D.J.
        • Alders M.
        • et al.
        An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing.
        Heart Rhythm. 2010; 7: 33-46
        • Wijeyeratne Y.D.
        • Tanck M.W.
        • Mizusawa Y.
        • et al.
        SCN5A mutation type and a genetic risk score associate variably with Brugada syndrome phenotype in SCN5A families.
        Circ Genom Precis Med. 2020; 13e002911
        • Bezzina C.R.
        • Barc J.
        • Mizusawa Y.
        • et al.
        Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death.
        Nat Genet. 2013; 45: 1044-1049
        • van Setten J.
        • Brody J.A.
        • Jamshidi Y.
        • et al.
        PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity.
        Nat Commun. 2018; 9: 2904
        • Arking D.E.
        • Pulit S.L.
        • Crotti L.
        • et al.
        Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization.
        Nat Genet. 2014; 46: 826-836
        • Sotoodehnia N.
        • Isaacs A.
        • de Bakker P.I.
        • et al.
        Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction.
        Nat Genet. 2010; 42: 1068-1076
        • Isaacs A.
        • Barysenka A.
        • Ter Bekke R.M.A.
        • et al.
        Standing genetic variation affects phenotypic heterogeneity in a SCN5A-mutation founder population with excess sudden cardiac death.
        Heart Rhythm. 2023; (XX:XX–XX)
        • Sugrue A.
        • van Zyl M.
        • Enger N.
        • et al.
        Echocardiography-guided risk stratification for long QT syndrome.
        J Am Coll Cardiol. 2020; 76: 2834-2843

      Linked Article